Long for a Longtime or until they make me an offer I cant' Refuse
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Time: Thursday, March 8, 3:45 p.m. EST and Friday, March 9, 4:15 p.m. EST
http://anavex.com/anavex-life-sciences-present-new-preclinical-data-20th-annual-meeting-american-society-experimental-neurotherapeutics-asent/
Wrong again.... time to cover or go broke... LOL!
TGD is at it again.... this time it will mean something... IMO
Christopher U Missling, Director of Anavex Life Sciences Corp. and a director of the company, recently acquired 1,650 shares of the company. The buys took place at $2.41 per share, on March 02, 2018. Missling now owns 1,013,900 shares of the company. Missling operates out of New York, NY. Some additional info was provided as follows:
The purchase reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 1, 2018.
https://www.sec.gov/Archives/edgar/data/1314052/000161577418001587/0001615774-18-001587-index.htm
I met and talked to the man at length.... Yes I believe
When anavex PR's the first basket CNS trial all you fudsters will eat your words... It will happen... Cover your shorts before they take your homes away...
Shorts loses are unlimited.
Time is running out...
GOFUNDME.COM is waiting....
There is a chance TGD is waiting for guidance approval for Rett and 2 other CNS trials... IMO 4/29
Anavex 2-73 Rett PH/2 first CNS drug trial being performed under the NEW precision medicine guidance... This may move the stock and get the attention of the MSM .......IMO
Just another piece of cheese....
“This clinical data together with prior preclinical findings seem to confirm ANAVEX 2-73’s selective activation of the specific stress reducing and survival protein, Sigma-1 receptor. This seems to present a potential common pathway for rescuing major neurodevelopmental and neurodegenerative disease mechanisms, like in Autism-related disorders and Alzheimer’s disease. I believe the distinct mechanistic nature suggests the compound could be a candidate treatment for a precision medicine approach across a spectrum of different neurological and psychiatric diseases,” said Professor Harald Hampel, MD, PhD, Professor and AXA Research Fund Chair at Sorbonne Universities’ Pierre and Marie Curie University (UPMC), Paris, France and member of Anavex’s Scientific Advisory Board.
Words of wisdom for the weekend...
"Struggles often serve to release the wisdom, patience, and strength we all possess but too seldom demonstrate."
Jim Stovall, Wisdom for Winners Volume One: A Millionaire Mindset
Thanks F1ash....
Could have been a waiting period before he was granted a board position.
The FDA has made it clear that they intend to make the process more efficient ($$$ and time) to bring these drugs to market.... Why do you think BP has dropped out...they lost their competitive edge $$$$$$$.
JMHO
Do some DD on past publications from the FDA on this subject.
This may be the most significant event we have seen in months... Like I said "Let's Get It ON!"
Anavex has followed the script..... Let's get it on!
https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM596728.pdf
Could be they are fitting the trial into the FDA's precision medicine guidelines.
I would feel I lost something if I lost millions... maybe more
Timing is everything!
Anavex is in the process of accommodating the FDA precision medicine approach to CNS drug trials. They promise to be shorter in duration and much more cost effective, while using the latest technologies.
All indications tell us the drug is safe and is more effective than any approved drugs.
We are starting three trials sometime this year.
Management is going it alone till the drug proves effective (MO $$$$)
TGD has the most to lose if it fails...
Good luck to all longs... Ignore the noise...
Must be something in the water!
TGD wants to use all available data to identify the biomarkers that 273 is the most effective on. Failure is not an option.. long and strong!
I guess I am greedy...
With good results...the stock price and partnerships will take care of them selves. Step back and look at the big picture...
Why would TGD make a deal now? Let's show proof the drug works and the numbers go way higher.. TGD is no fool.
You got my sticky vote...Good post
Dr. G did get a new boss which probably had something to do with the delay of the 5 guidances. We also have the corrupt FDA that is owned by BP and the swamp dwellers that BP supports.
Tom
I have maintained for a log time that gaps on AVXL always fill.. works both ways ... next gap around $4.30.. Bought some today around gap fill. GLTAL
Believe what you may... I have lived it through this stock and a few others.. some broker who lost his licence over a report he wrote on it, described the process to a tee... I will see if I can find the article for you.
I guess you haven't been here very long... The rise to $14 and fall WAS TEXT BOOK MANIPULATION.
I will buy more...
good target... some strong hands will have break even stops.
I still haven't seen any negative news.